Agilent Technologies has agreed to acquire Proscia, a digital pathology software company, for $240 million in cash, with up to $30 million more tied to future performance milestones.
The deal would add a software platform to Agilent’s existing pathology products as it expands into digital and AI-enabled diagnostics.
The companies already work together. Since 2022, they have partnered to offer a digital pathology system that combines Agilent products with Proscia’s software.
The acquisition would bring that software business inside Agilent, pending customary closing conditions. The companies expect the deal to close early in Agilent’s fiscal 2027.
What Agilent is buying
Pathology labs traditionally examine tissue samples on glass slides under a microscope. Digital pathology converts those slides into high-resolution images that can be stored, shared, and analyzed using software.
Proscia’s platform helps labs manage those images and connect them with laboratory systems and image-analysis tools.
Agilent says Proscia serves more than 4,000 laboratories, hospitals, and clinics, as well as 16 of the 20 largest pharmaceutical companies. Its revenue exceeded $18 million over the 12 months before the announcement.
Agilent says Proscia’s platform has FDA 510(k) clearance for primary diagnosis. That clearance is relevant to clinical use, while the company also serves research and drug-development customers.
Why the software matters
Agilent already sells pathology instruments and reagents. Adding software could let it offer customers a more connected workflow—from preparing and scanning tissue samples to managing and analyzing the resulting images.
That combination may also support Agilent’s work with pharmaceutical companies on biomarker research and companion diagnostics.
These tools help researchers identify biological features that may guide treatment decisions or indicate which patients are most likely to benefit from a medicine.
The strategic opportunity is to connect products that labs might otherwise buy from different suppliers.
The challenge is making the combined system work smoothly across the scanners, lab information systems, and analysis applications that customers already use.
A modest-sized deal with a broader purpose
Proscia’s reported trailing revenue of more than $18 million is small compared with Agilent’s overall business.
The acquisition’s value therefore rests partly on what the software could enable: recurring revenue, stronger customer relationships, and a larger role in digital pathology.
Agilent describes Proscia as a high-growth, high-margin software business. Those are management’s expectations; the companies have not disclosed detailed financial projections for the combined business.
Agilent will also need to integrate Proscia’s team and products while maintaining customer confidence in the platform.
The acquisition announcement describes the intended benefits, but those benefits will depend on execution after closing.
What to watch next
The deal is expected to close early in Agilent’s fiscal 2027. Until then, it remains a proposed acquisition.
After closing, useful indicators will include how quickly Agilent integrates Proscia’s software with its pathology portfolio, whether customers adopt the combined offering, and whether the business delivers the growth and recurring revenue Agilent expects.
For now, the deal signals that Agilent sees software as an increasingly important part of its pathology strategy.
Buying Proscia gives it a larger digital foothold; turning that foothold into measurable growth is the next test.
